Reduction of Intestinal Neoplasia With Adenomatous Polyposis Coli Gene Replacement and COX-2 Inhibition Is Additive
Authors:
- John I LewJLJohn I Lew
- Yuee GuoYGYuee Guo
- Richard K KimRKRichard K Kim
- Lisa VargishLVLisa Vargish
- Fabrizio MichelassiFMFabrizio Michelassi
- Richard B ArenasRARichard B Arenas
- 1 July 2002
- journal article
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 6 (4) , 563-568
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Identification of c- MYC as a Target of the APC PathwayScience, 1998
- The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposisCarcinogenesis, 1998
- Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression.1997
- Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APCScience, 1997
- Introduction of human adenomatous polyposis coli gene into Min mice via cationic liposomesSurgery, 1996
- Apoptosis and APC in colorectal tumorigenesis.Proceedings of the National Academy of Sciences of the United States of America, 1996
- Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis.1995
- Loss of Apc+ in intestinal adenomas from Min mice.1994
- APC mutations occur early during colorectal tumorigenesisNature, 1992
- Multiple Intestinal Neoplasia Caused by a Mutation in the Murine Homolog of the APC GeneScience, 1992